Physician profile
Taaly Silberstein
NPI 1518993708
$3,047.24
in general payments reported to CMS, 2019-2025
21 companies · $978 in 2025
The $978 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $185 · 2021: $214 · 2022: $314 · 2023: $139 · 2024: $1,031 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,600 · Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,600.00 |
| Food and Beverage | $547.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,600.00 | 2024-2025 | Bovine Collagen |
| Pfizer INC. | $288.98 | 2020-2024 | |
| Hologic Sales and Service, LLC | $161.37 | 2022-2025 | Aptima |
| Avion Pharmaceuticals | $141.66 | 2019-2021 | |
| Organon LLC | $139.09 | 2024 | |
| Mayne Pharma Commercial LLC | $132.07 | 2021-2025 | |
| Abbvie INC. | $121.59 | 2021-2023 | Liletta |
| Therapeuticsmd, INC. | $91.84 | 2019-2021 | |
| Minerva Surgical, INC | $65.18 | 2019 | |
| Astellas Pharma US INC | $47.50 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $34.42 | 2022 | |
| Amag Pharmaceuticals, INC. | $33.58 | 2019 | |
| Sage Therapeutics, LLC | $29.90 | 2024 | |
| Allergan, INC. | $25.51 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.37 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic INC | $23.34 | 2021 | |
| Exeltis, USA INC. | $23.06 | 2021 | |
| Channel Medsystems, INC. | $20.93 | 2022 | |
| Coopersurgical, INC. | $18.77 | 2024 | Paragard T 380a |
| Merz North America, INC. | $12.55 | 2020 | |
| Duchesnay USA Incorporated | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taaly Silberstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.